WIL-1901 is under clinical development by Whan In Pharm and currently in Phase I for Dementia Associated With Alzheimer’s Disease. According to GlobalData, Phase I drugs for Dementia Associated With Alzheimer’s Disease have a 94% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how WIL-1901’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
WIL-1901 is under development for the treatment of dementia associated with Alzheimer's disease. It is a incrementally modified drug (IMD) candidate.
Whan In Pharm overview
Whan In Pharm (Whan In Pharma) develops, manufactures and supplies pharmaceutical products. The company’s product range includes anti-depressants, anti-psychotics, nootropics and anti-dementia, anti-epileptics, antibiotics, anti-viral agents, anti-histamines, anti-inflammatory drugs and analgesics. It also produces drugs for the treatment of central nervous system, cardiovascular, gastrointestinal, metabolic and respiratory disorders. Whan In Pharma is investigating therapies against dementia, Parkinson’s disease, cancer, epilepsy, alcoholism, depression, and chronic arterial obstruction. The company offers its products in the forms of tablets, capsules and injections. It works in collaboration with companies across Europe, the US, and India. Whan In Pharm is headquartered in Seoul, South Korea.
For a complete picture of WIL-1901’s drug-specific PTSR and LoA scores, buy the report here.